BI 425809
Showing 1 - 25 of 1,399
Healthy Trial in Mannheim (Microgynon®, BI 425809)
Recruiting
- Healthy
- Microgynon®
- BI 425809
-
Mannheim, GermanyCRS Clinical Research Services Mannheim GmbH
Jan 30, 2023
Healthy Trial (BI 425809)
Not yet recruiting
- Healthy
- BI 425809
- (no location specified)
Aug 10, 2022
Healthy Trial in Biberach (midazolam, BI 425809)
Completed
- Healthy
- midazolam
- BI 425809
-
Biberach, GermanyHumanpharmakologisches Zentrum Biberach
Jun 2, 2022
Hepatic Insufficiency Trial (BI 425809 (iclepertin))
Not yet recruiting
- Hepatic Insufficiency
- BI 425809 (iclepertin)
- (no location specified)
Feb 8, 2023
Healthy Trial in Biberach (BI 425809, fluconazole)
Completed
- Healthy
- BI 425809
- fluconazole
-
Biberach, GermanyHumanpharmakologisches Zentrum Biberach
Jan 11, 2022
Renal Insufficiency Trial in Kiel (BI 425809)
Recruiting
- Renal Insufficiency
- BI 425809
-
Kiel, GermanyCRS Clinical Research Services Kiel GmbH
Feb 9, 2023
Schizophrenia Trial in Worldwide (BI 425809)
Recruiting
- Schizophrenia
- BI 425809
-
Anaheim, California
- +37 more
Aug 8, 2022
Healthy Trial in Mannheim (BI 425809, Memantine)
Completed
- Healthy
- BI 425809
- Memantine
-
Mannheim, GermanyCRS Clinical Research Services Mannheim GmbH
Mar 18, 2021
Healthy Trial in Mannheim (BI 425809, Donepezil)
Completed
- Healthy
- BI 425809
- Donepezil
-
Mannheim, GermanyCRS Clinical Research Services Mannheim GmbH
Jan 27, 2021
Schizophrenia Trial in Worldwide (BI 425809, Placebo)
Completed
- Schizophrenia
- BI 425809
- Placebo
-
Little Rock, Arkansas
- +50 more
Nov 7, 2022
Schizophrenia Trial in Worldwide (BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3)
Completed
- Schizophrenia
- BI 425809 dose 1
- +4 more
-
Garden Grove, California
- +80 more
Feb 5, 2021
Alzheimer Trial in Worldwide (BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3)
Completed
- Alzheimer Disease
- BI 425809 dose 1
- +4 more
-
Colton, California
- +94 more
Oct 16, 2020
Healthy Trial in Biberach (BI 425809 (Treatment T1), BI 425809 (Treatment T2), BI 425809 (Treatment R))
Completed
- Healthy
- BI 425809 (Treatment T1)
- +2 more
-
Biberach, GermanyHumanpharmakologisches Zentrum Biberach
Jun 3, 2019
Healthy Trial in Groningen (BI 425809, BI 425809 mixed with [C-14]-BI 425809)
Completed
- Healthy
- BI 425809
- BI 425809 mixed with [C-14]-BI 425809
-
Groningen, NetherlandsPRA Health Sciences Onderzoekscentrum Martini
Mar 12, 2019
Healthy Trial in Groningen (BI 425809 mixed with [C-14] BI425809)
Completed
- Healthy
- BI 425809 mixed with [C-14] BI425809
-
Groningen, NetherlandsPRA Health Sciences Onderzoekscentrum Martini
Nov 16, 2018
Adolescent Cancer, Young Adult Cancer, Body Image Trial in Ann Arbor (BI Focused writing, Control)
Not yet recruiting
- Adolescent Cancer
- +2 more
- BI Focused writing
- Control
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Sep 13, 2023
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, NSCLC (NSCLC) Trial in Amsterdam (BI 765063, Ezabenlimab, [89Zr]Zr-
Recruiting
- Carcinoma, Squamous Cell of Head and Neck (HNSCC)
- +2 more
- BI 765063
- +4 more
-
Amsterdam, NetherlandsAmsterdam UMC Locatie VUMC
Jan 9, 2023
Healthy Trial (BI 1015550)
Not yet recruiting
- Healthy
- BI 1015550
- (no location specified)
Nov 15, 2023
Tumors Trial in Spain, United Kingdom, United States (BI 1387446, BI 754091)
Active, not recruiting
- Neoplasms
- BI 1387446
- BI 754091
-
Chapel Hill, North Carolina
- +7 more
Jan 23, 2023
Myocardial Infarction Trial (BI 765845, Placebo matching BI 765845)
Not yet recruiting
- Myocardial Infarction
- BI 765845
- Placebo matching BI 765845
- (no location specified)
Nov 15, 2023
Hernia, Inguinal Trial (Erector spinae plane block)
Not yet recruiting
- Hernia, Inguinal
- Erector spinae plane block
- (no location specified)
Nov 30, 2023
Solid Tumor, KRAS Mutation Trial (BI 3706674)
Not yet recruiting
- Solid Tumor, KRAS Mutation
- BI 3706674
- (no location specified)
Sep 29, 2023
Healthy Trial (BI 1810631 (C-14) formulation 1, BI 1810631, BI 1810631 (C-14) formulation 2)
Not yet recruiting
- Healthy
- BI 1810631 (C-14) formulation 1
- +2 more
- (no location specified)
May 25, 2023